Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 4,662 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Therapy Clear all
Completed Phase 1 Interventional Results available

Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

NCT01924689
View directory record Official record
Conditions
Solid Tumor Malignancies
Interventions
Clostridium novyi-NT spores
Biological
Lead sponsor
BioMed Valley Discoveries, Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
St Louis, Missouri • New York, New York • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 21, 2026, 6:59 AM EDT
Completed No phase listed Observational

Oncology Research Information Exchange Network (ORIEN) Lung Cancer Study

NCT02803333
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer
Interventions
No Intervention
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 21, 2026, 6:59 AM EDT
Terminated No phase listed Observational

A Biomarker Screening Protocol for Participants With Solid Tumors

NCT05891197
View directory record Official record
Conditions
Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer
Interventions
Not listed
Lead sponsor
Lyell Immunopharma, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Rocky Mount, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 4 Interventional Results available

Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan

NCT01051960
View directory record Official record
Conditions
Systemic Sclerosis, Shortness of Breath, Pulmonary Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Not applicable Interventional

Respiration Rate Monitoring in COPD Patients

NCT03030313
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Reassure Non-Contact Respiration Monitor
Device
Lead sponsor
ResMed
Industry
Eligibility
35 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 21, 2026, 6:59 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Obstructive Sleep Apnea (OSA) in Pulmonary Arterial Hypertension (PAH)

NCT01835080
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

NCT03912233
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121, TEZ, VX-561, TEZ/IVA, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
12
States / cities
Los Angeles, California • Oakland, California • Lexington, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 21, 2026, 6:59 AM EDT
Active, not recruiting Not applicable Interventional Results available

Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)

NCT05092516
View directory record Official record
Conditions
Dysexecutive Syndrome, Post-Acute Sequelae of COVID-19
Interventions
Active tDCS, Sham tDCS
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 21, 2026, 6:59 AM EDT
Withdrawn Phase 3 Interventional

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT00760916
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
UT-15C 1 mg, UT-15C 0.25 mg, UT-15C 5 mg, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 21, 2026, 6:59 AM EDT
Withdrawn Phase 4 Interventional

Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis

NCT02547116
View directory record Official record
Conditions
Cystic Fibrosis, MRSA
Interventions
Rifampin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 21, 2026, 6:59 AM EDT
Recruiting Phase 2 Interventional

Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer

NCT07216404
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Unipolar Depression
Interventions
Biospecimen Collection, Counseling, Interview, Psilocybin, Survey Administration
Procedure · Other · Drug
Lead sponsor
Alan Davis
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 21, 2026, 6:59 AM EDT
Recruiting Phase 2 Interventional

Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer

NCT07423585
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Electronic Health Record Review, Magnetic Resonance Imaging, Multigated Acquisition Scan, Questionnaire Administration, Tarlatamab
Procedure · Other · Drug
Lead sponsor
Asrar Alahmadi
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Not applicable Interventional

Music Therapy in the Treatment of Chronic Obstructive Pulmonary Disease

NCT02146235
View directory record Official record
Conditions
Pulmonary Diseases
Interventions
Psycho-Music Therapy
Behavioral
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
45 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 21, 2026, 6:59 AM EDT
Terminated Not applicable Interventional Results available

Oscillation and Lung Expansion (OLE) Therapy for Treatment of Neuromuscular Disease (NMD) Patients

NCT05366010
View directory record Official record
Conditions
Neuromuscular Diseases
Interventions
Oscillation and Lung Expansion (OLE) therapy
Device
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
5 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 3 Interventional

Multi-site Adaptive Trials for COVID-19

NCT04370262
View directory record Official record
Conditions
COVID-19
Interventions
SOC + Intravenous Famotidine, SOC + Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Bay Shore, New York • Manhasset, New York • Mount Kisco, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 21, 2026, 6:59 AM EDT
Recruiting Not applicable Interventional

SMART@Home Feasibility Trial

NCT06159127
View directory record Official record
Conditions
Asthma, Asthma in Children
Interventions
SMART@Home
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 6:59 AM EDT
Recruiting Phase 1 Interventional

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

NCT07006727
View directory record Official record
Conditions
Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma, Non-prostate Extrapulmonary Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Thymic Neuroendocrine Carcinoma, Genitourinary Neuroendocrine Carcinoma, Unknown Primary Neuroendocrine Carcinomas, Merkel Cell Carcinoma, Medullary Thyroid Carcinoma
Interventions
225Ac-ETN029, 111In-ETN029
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
4
States / cities
Iowa City, Iowa • Boston, Massachusetts • Royal Oak, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 2 Interventional Results available

Montelukast to Treat Bronchiolitis Obliterans

NCT00656058
View directory record Official record
Conditions
Bronchiolitis Obliterans, Chronic Graft Versus Host Disease, Leukotriene, Montelukast, Stem Cell Transplant
Interventions
Singulair (Montelukast Sodium)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
6 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Oct 21, 2026, 6:59 AM EDT
Not listed No phase listed Observational

Impact of Asthma Treatments on Daily Activities

NCT00350376
View directory record Official record
Conditions
Asthma, Allergies
Interventions
Not listed
Lead sponsor
Ovation Research Group
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,500 participants
Timeline
Started 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2006 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma

NCT00467740
View directory record Official record
Conditions
Asthma
Interventions
BI 1744 CL
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
10
States / cities
Lakewood, California • Los Angeles, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 2 Interventional

PT005 MDI Dose Ranging Versus Foradil Aerolizer Study

NCT01349868
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT005 MDI, Formoterol Fumarate 12 μg (Foradil® Aerolizer®), Formoterol Fumarate 24 μg (Foradil® Aerolizer®), Placebo MDI
Drug · Other
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
3
States / cities
Clearwater, Florida • Tampa, Florida • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2012 · Synced Oct 21, 2026, 6:59 AM EDT
Completed No phase listed Observational

Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Non-Small Cell Lung Cancer And Bronchial Disease

NCT00754910
View directory record Official record
Conditions
Lung Cancer
Interventions
porfimer sodium, bronchoscopy
Drug · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 2Phase 3 Interventional

Enabling Sleep Apnea Patient-Centered Care Via an Internet Intervention

NCT00662623
View directory record Official record
Conditions
Sleep Apnea Syndromes
Interventions
i-PAP, Usual Care (Standard Care)
Behavioral
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Not applicable Interventional Results available

Duration of Antibiotic Treatment for Early VAP (DATE) Trial

NCT01994980
View directory record Official record
Conditions
Early Ventilator Associated Pneumonia
Interventions
Default 4 days antibiotic therapy
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 21, 2026, 6:59 AM EDT